Nanocarrier-Based Drug Delivery to Brain: Interventions of Surface Modification

Curr Neuropharmacol. 2023;21(3):517-535. doi: 10.2174/1570159X20666220706121412.

Abstract

Brain disorders are a prevalent and rapidly growing problem in the medical field as they adversely affect the quality of life of a human. With an increase in life expectancy, it has been reported that diseases like Alzheimer's, Parkinson's, stroke and brain tumors, along with neuropsychological disorders, are also being reported at an alarmingly high rate. Despite various therapeutic methods for treating brain disorders, drug delivery to the brain has been challenging because of a very complex Blood Brain Barrier, which precludes most drugs from entering the brain in effective concentrations. Nano-carrier-based drug delivery systems have been reported widely by researchers to overcome this barrier layer. These systems due to their small size, offer numerous advantages; however, their short residence time in the body owing to opsonization hinders their success in vivo. This review article focuses on the various aspects of modifying the surfaces of these nano-carriers with polymers, surfactants, protein, antibodies, cell-penetrating peptides, integrin binding peptides and glycoproteins such as transferrin & lactoferrin leading to enhanced residence time, desirable characteristics such as the ability to cross the blood-brain barrier (BBB), increased bioavailability in regions of the brain and targeted drug delivery.

Keywords: Blood brain barrier; CNS disorders; antibodies; lactoferrin; mucoadhesive; nanoparticles; surface modification; transferrin.

Publication types

  • Review

MeSH terms

  • Blood-Brain Barrier / metabolism
  • Brain / metabolism
  • Brain Diseases* / metabolism
  • Drug Delivery Systems / methods
  • Humans
  • Nanoparticles*
  • Quality of Life